Compass Pathways is exploding higher following the release of positive 52-week topline data from its Phase 3 COMP005 trial, which demonstrated the lasting durability of its COMP360 psilocybin treatment for treatment-resistant depression. This momentum builds on the company's announcement from the previous day regarding its upcoming participation at Psych Congress 2026, where it plans to debut a new healthcare professional education campaign and present additional health economics and outcomes research data. The stock has now reached a new 52-week high, reflecting strong investor confidence in the long-term efficacy results reported in the open-label Part C study.